

# US company poised to start COVID-19 vaccine safety test

6 April 2020



made using a section of the virus' [genetic code](#) packaged inside a piece of synthetic DNA.

© 2020 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed without permission.

Credit: CC0 Public Domain

A second U.S. company is poised to begin a small safety test of a vaccine against the new coronavirus.

Inovio Pharmaceuticals said Monday that it has Food and Drug Administration permission for the study in 40 [healthy volunteers](#) in Philadelphia and Kansas City, Missouri.

The study is a first step to see if the [vaccine](#) appears safe enough for larger tests needed to prove whether it will protect. Even if the research goes well, it is expected to take over a year before any vaccine could be widely available.

Last month, the first safety [test](#) in people of a different vaccine candidate began in Seattle. It was developed by the National Institutes of Health and Moderna Inc.

Numerous other research groups are attempting to make vaccines against COVID-19 using a variety of different methods in hopes at least one will offer protection.

Inovio's approach is what's called a DNA vaccine,

APA citation: US company poised to start COVID-19 vaccine safety test (2020, April 6) retrieved 9 November 2022 from <https://medicalxpress.com/news/2020-04-company-poised-covid-vaccine-safety.html>

*This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.*